Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
Gut|September 5, 2020
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumoursKate Young, Rita T Lawlor, Chanthirika Ragulan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
Cancer Medicine|May 8, 2024
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trialKen Kato, Yuichiro Doki, Ian Chau, et al.
Clinical Colorectal Cancer|June 22, 2019
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)Rachel P Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Pageof 28